蒙药抗绝经后骨质疏松的研究进展
Research Progress of Mongolian Medicine against Postmenopausal Osteoporosis
DOI: 10.12677/acm.2024.14102771, PDF,   
作者: 包玉龙：内蒙古医科大学研究生学院，内蒙古 呼和浩特；佟雁翔*：内蒙古医科大学第二附属医院创伤外科中心A区，内蒙古 呼和浩特
关键词: 蒙药；骨质疏松；绝经后骨质疏松；Mongolian Medicine； Osteoporosis； Postmenopausal Osteoporosis
摘要: 骨质疏松症(osteoporosis, OP)是最为常见的十种疾病之一，随着我国人口老龄化，骨质疏松患者逐年增加，尤其是绝经后女性远大于男性。绝经后骨质疏松症(postmenopausal osteoporosis, PMOP)在OP中发病率最高的一种，其发生与雌激素分泌降低，体力活动减少，营养不平衡或相对不足，以及随年龄增加，机体衰老、损伤和修复的变化，以及骨细胞和组织增殖、分化、功能减退等内在因素的综合作用所致，除此之外氧化应激、肠道菌群和铁过载都会影响PMOP的发病。蒙医称OP为“骨枯症”，本研究从蒙医对骨质疏松的药物疗法进行分析研究和展望。
Abstract: Osteoporosis (OP) is one of the ten most common diseases. With the aging of the population, the number of osteoporosis patients has increased year by year, especially postmenopausal women are much more than men. Postmenopausal osteoporosis (PMOP) is one of the most common forms of OP. Its occurrence is associated with decreased estrogen secretion, reduced physical activity, nutritional imbalance or relative insufficiency, and changes in aging, injury and repair as the body ages, as well as intrinsic factors such as bone cell and tissue proliferation, differentiation and dysfunction. In addition, oxidative stress, intestinal flora and iron overload affect the pathogenesis of PMOP. OP is called “bone blight disease” in Mongolian medicine. This study analyzed and studied the drug therapy of osteoporosis from Mongolian medicine.
文章引用：包玉龙, 佟雁翔. 蒙药抗绝经后骨质疏松的研究进展[J]. 临床医学进展, 2024, 14(10): 1086-1092. https://doi.org/10.12677/acm.2024.14102771

参考文献

[1] Kanis, J.A., Melton, L.J., Christiansen, C., Johnston, C.C. and Khaltaev, N. (1994) The Diagnosis of Osteoporosis. Journal of Bone and Mineral Research, 9, 1137-1141. [Google Scholar] [CrossRef] [PubMed]
[2] 葛继荣, 王和鸣, 郑洪新, 等. 中医药防治原发性骨质疏松症专家共识(2020) [J]. 中国骨质疏松杂志, 2020, 26(12): 1717-1725.
[3] 汤淑女, 尹香君, 余卫, 等. 中国40岁及以上绝经后女性骨质疏松症患病率及其影响因素研究[J]. 中华流行病学杂志, 2022, 43(4): 509-516.
[4] 谢雁鸣, 刘峘, 姜俊杰, 等. 绝经后骨质疏松症中医临床实践指南(征求意见稿) [J]. 中国中药杂志, 2021, 46(22): 5992-5998.
[5] Goeree, R., Burke, N., Jobin, M., Brown, J.P., Lawrence, D., Stollenwerk, B., et al. (2022) Cost-Effectiveness of Romosozumab for the Treatment of Postmenopausal Women at Very High Risk of Fracture in Canada. Archives of Osteoporosis, 17, Article No. 71. [Google Scholar] [CrossRef] [PubMed]
[6] Cooper, C. (1997) The Crippling Consequences of Fractures and Their Impact on Quality of Life. The American Journal of Medicine, 103, S12-S19. [Google Scholar] [CrossRef] [PubMed]
[7] Brown, J.P., Adachi, J.D., Schemitsch, E., Tarride, J., Brown, V., Bell, A., et al. (2021) Mortality in Older Adults Following a Fragility Fracture: Real-World Retrospective Matched-Cohort Study in Ontario. BMC Musculoskeletal Disorders, 22, Article No. 105. [Google Scholar] [CrossRef] [PubMed]
[8] Marie, P.J. and Kassem, M. (2011) Extrinsic Mechanisms Involved in Age-Related Defective Bone Formation. The Journal of Clinical Endocrinology & Metabolism, 96, 600-609. [Google Scholar] [CrossRef] [PubMed]
[9] Kassem, M. and Marie, P.J. (2011) Senescence-Associated Intrinsic Mechanisms of Osteoblast Dysfunctions. Aging Cell, 10, 191-197. [Google Scholar] [CrossRef] [PubMed]
[10] 夏绍祥, 陈亮. OPG/RANKL/RANK系统在绝经后骨质疏松中的调节作用[J]. 中国骨质疏松杂志, 2013, 19(1): 74-78.
[11] Abu-Amer, Y. (2013) NF-κB Signaling and Bone Resorption. Osteoporosis International, 24, 2377-2386. [Google Scholar] [CrossRef] [PubMed]
[12] Cheng, C., Chen, L. and Chen, K. (2022) Osteoporosis Due to Hormone Imbalance: An Overview of the Effects of Estrogen Deficiency and Glucocorticoid Overuse on Bone Turnover. International Journal of Molecular Sciences, 23, Article 1376. [Google Scholar] [CrossRef] [PubMed]
[13] 邹聪, 孙晓鹏, 付冰冰. 骨保护素研究新进展[J]. 黑龙江医药, 2020, 33(6): 1274-1277.
[14] Han, X.G., Wang, D.W., Bi, Z.G., et al. (2016) Regulatory Effect of Estrogen Receptor-α-Mediated Wnt/β-Catenin Signaling Pathway on Osteoblast Proliferation. Journal of Biological Regulators and Homeostatic Agents, 30, 381-387.
[15] 张萌萌. 雌激素与雌激素受体骨代谢调节作用[J]. 中国骨质疏松杂志, 2019, 25(5): 704-708.
[16] Almeida, M., Iyer, S., Martin-Millan, M., Bartell, S.M., Han, L., Ambrogini, E., et al. (2012) Estrogen Receptor-α Signaling in Osteoblast Progenitors Stimulates Cortical Bone Accrual. Journal of Clinical Investigation, 123, 394-404. [Google Scholar] [CrossRef] [PubMed]
[17] Wang, X., Chen, B., Sun, J., Jiang, Y., Zhang, H., Zhang, P., et al. (2018) Iron-induced Oxidative Stress Stimulates Osteoclast Differentiation via NF-κB Signaling Pathway in Mouse Model. Metabolism, 83, 167-176. [Google Scholar] [CrossRef] [PubMed]
[18] 李丽娟, 林静, 王凌. 肠道微生态影响绝经后骨质疏松症发生发展的研究进展[J]. 中国免疫学杂志, 2019, 35(16): 2032-2037.
[19] 李光飞, 徐又佳. 铁蓄积与绝经后骨质疏松症关系的研究进展[J]. 中华骨科杂志, 2015, 35(10): 1017-1021.
[20] 中华医学会骨质疏松和骨矿盐疾病分会. 原发性骨质疏松症诊治指南(2017年) [J]. 中华骨质疏松和骨矿盐疾病杂志, 2017(9): 415-416.
[21] 史晓林, 王和鸣, 高毅, 等. 绝经后骨质疏松症(骨痿)中医药诊疗指南(2019年版) [J]. 中医正骨, 2020, 32(2): 1-13.
[22] 孟克布和, 斯钦图. 初探蒙医诊治骨质疏松症[J]. 中国民族医药杂志, 2011, 17(1): 70-71.
[23] Brown, J.P., Don-Wauchope, A., Douville, P., Albert, C. and Vasikaran, S.D. (2022) Current Use of Bone Turnover Markers in the Management of Osteoporosis. Clinical Biochemistry, 109, 1-10. [Google Scholar] [CrossRef] [PubMed]
[24] 图布新, 通啦嘎, 包海金, 等. 蒙药壮西-4调控miR-204对骨质疏松大鼠成骨细胞增殖的影响及机制[J]. 中国老年学杂志, 2024, 44(5): 1124-1128.
[25] 图布新, 辛颖, 李桂花, 等. 蒙药壮西-4味散对维甲酸诱导大鼠骨质疏松的治疗作用[J]. 中国老年学杂志, 2022, 42(14): 3558-3561.
[26] 乌日汗. 蒙药壮西-4味散联合碳酸钙D3片治疗绝经后骨质疏松症的临床研究[D]: [硕士学位论文]. 通辽: 内蒙古民族大学, 2023.
[27] 赵军, 赵立新, 师建平, 等. 蒙药塔布森-2对于去卵巢大鼠骨质疏松软骨细胞自噬的作用[J]. 中国民族医药杂志, 2024, 30(3): 38-44.
[28] 王曦悦, 陆景坤, 董馨, 等. 蒙药塔布森-2对斑马鱼糖皮质激素性骨质疏松的改善作用[J]. 中华中医药杂志, 2024, 39(1): 372-376.
[29] 田显庭, 薛培凤, 张廉居, 等. 基于HPLC-Q-Exactive-MS/MS整合网络药理学研究加味塔布森-2有效成分及其抗骨质疏松机制[J]. 中国现代应用药学, 2022, 39(13): 1668-1676.
[30] Sims, N.A. and Martin, T.J. (2014) Coupling the Activities of Bone Formation and Resorption: A Multitude of Signals within the Basic Multicellular Unit. BoneKEy Reports, 3, Article 481. [Google Scholar] [CrossRef] [PubMed]
[31] 方婷. 基于PI3K/AKT/mTOR信号通路蒙药蓝刺头防治绝经后骨质疏松症的实验研究[D]: [硕士学位论文]. 呼和浩特: 内蒙古医科大学, 2023.
[32] 孙振双, 郭海英. 温肾固疏方调控FoxO/Wnt信号通路抗氧化应激防治绝经后骨质疏松的机制研究[D]: [博士学位论文]. 南京: 南京中医药大学, 2017.
[33] 赵军, 李昕, 刘岩, 等. 蒙药蓝刺头对去卵巢大鼠BGP、BMD及股骨组织形态的影响[J]. 西部中医药, 2023, 36(6): 6-10.
[34] Liu, Y., Wang, X., Chang, H., Gao, X., Dong, C., Li, Z., et al. (2018) Mongolian Medicine Echinops Prevented Postmenopausal Osteoporosis and Induced ER/AKT/ERK Pathway in BMSCs. BioScience Trends, 12, 275-281. [Google Scholar] [CrossRef] [PubMed]
[35] 赵军, 李昕, 刘晋, 等. 蒙药蓝刺头对去卵巢大鼠TGF-β1、BMD及子宫组织形态的影响[J]. 西部中医药, 2021, 34(10): 30-33.
[36] 赵军, 师建平, 董重阳, 等. 蒙药蓝刺头对绝经后骨质疏松症大鼠瘦素、β2肾上腺素受体的影响[J]. 西部中医药, 2021, 34(3): 72-76.
[37] 赵军, 董重阳, 李昕, 等. 蒙药蓝刺头抗PMOP骨组织计量学研究[J]. 西部中医药, 2020, 33(5): 63-66.
[38] 巴音他拉. 蒙药那仁满都拉-11味丸治疗原发性骨质疏松症的临床研究[D]: [硕士学位论文]. 通辽: 内蒙古民族大学, 2023.
[39] 余自层, 郭杨, 马勇, 等. 蒙药那仁满都拉调控Wnt/β-catenin信号通路抗骨质疏松的作用及机制[J]. 中国骨质疏松杂志, 2023, 29(1): 58-63, 69.
[40] Xiao, J., Yu, Z., Han, Q., Guo, Y., Ye, J., Lian, H., et al. (2024) The Mechanism of Action and Experimental Verification of Narenmandula in the Treatment of Postmenopausal Osteoporosis. Combinatorial Chemistry & High Throughput Screening, 27, 2249-2259. [Google Scholar] [CrossRef] [PubMed]
[41] 乌云必力格. 蒙药润骨灵治疗绝经后骨质疏松症小鼠的疗效及作用机制研究[D]: [硕士学位论文]. 呼和浩特: 内蒙古医科大学, 2023.
[42] 龚利民. 蒙药润骨灵治疗骨质疏松症临床研究[D]: [硕士学位论文]. 呼和浩特: 内蒙古医科大学, 2020.
[43] 秦雄, 韩巴根那, 马瑞瑞. 蒙药加减通拉嘎-5对维甲酸所致大鼠骨质疏松的治疗作用[J]. 内蒙古民族大学学报(自然科学版), 2014, 29(1): 74-76.
[44] 前达门. 蒙药“加味通拉嘎-5”治疗骨质疏松的临床研究[D]: [硕士学位论文]. 呼和浩特: 内蒙古医科大学, 2022.
[45] 王欢欢, 安义, 张聚良, 等. 蒙药参竹精片治疗骨质疏松症临床疗效观察[J]. 中国民族医药杂志, 2017, 23(8): 8-10.
[46] 董重阳. 蒙药二味杜仲汤对去卵巢大鼠骨代谢无机元素影响的实验研究[D]: [硕士学位论文]. 呼和浩特: 内蒙古医学院, 2010.
[47] 吴佳宝. 二味杜仲汤调控Rhoa/Rock通路防治绝经后骨质疏松症的作用机制研究[D]: [硕士学位论文]. 呼和浩特: 内蒙古医科大学, 2023.
[48] 杨帆, 张秀艳, 董馨, 等. 二味杜仲汤对D-半乳糖诱导骨质疏松大鼠的影响[J]. 中成药, 2022, 44(4): 1291-1294.
[49] 包立道, 郭秀琴, 王玉华, 等. 蒙药亚苏哈图吉呼对去卵巢骨质疏松小鼠的实验研究[J]. 中国民族医药杂志, 2006, 12(2): 32-33.

为你推荐